anyone else notice amylin kicking in around week 36
anyone else notice amylin kicking in around week 36, and the part I actually want to talk about is at the bottom.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
the monotherapy numbers are modest and that is not the point
Which receptor family are you attributing that effect to?
nothing containing this is approved as a standalone product
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.